- Home
- LRHC vs ONCO Comparison
LRHC vs ONCO Comparison
Compare LRHC & ONCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | LRHC | ONCO |
|---|---|---|
| Founded | 2004 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7M | 1.4M |
| IPO Year | 2022 | 2021 |
Fundamental Metrics
Financial Performance| Metric | LRHC | ONCO |
|---|---|---|
| Price | $1.08 | $1.06 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 138.9K | ★ 4.1M |
| Earning Date | 05-28-2026 | 06-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 26.17 | 22.80 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $69,448,786.00 | $815,371.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 118.67 | N/A |
| 52 Week Low | $0.08 | $0.07 |
| 52 Week High | $11.21 | $7.65 |
Technical Indicators
Market Signals| Indicator | LRHC | ONCO |
|---|---|---|
| Relative Strength Index (RSI) | 39.44 | 57.85 |
| Support Level | $0.98 | $0.49 |
| Resistance Level | $1.25 | $1.44 |
| Average True Range (ATR) | 0.13 | 0.10 |
| MACD | -0.04 | 0.05 |
| Stochastic Oscillator | 7.29 | 71.83 |
Price Performance
Historical ComparisonAbout LRHC La Rosa Holdings Corp.
La Rosa Holdings Corp operates in the U.S. residential real estate market. It is a holding company for agent-centric, technology-integrated, cloud-based, multi-service real estate companies. The company's business is organized based on the services it provides internally to the agents and to the public, which are residential and commercial real estate brokerage, franchising, real estate brokerage education and coaching, and property management. The company has six reportable segments, namely: Real Estate Brokerage Services (Residential), Franchising Services, Coaching Services, Property Management, Real Estate Brokerage Services (Commercial), and Title Settlement and Insurance. It derives maximum revenue from the Real Estate Brokerage Services (Residential) segment.
About ONCO Onconetix Inc.
Onconetix Inc is a commercial-stage biotechnology company focused on the research, development, and commercialization of solutions for men's health and oncology. The company owns Proclarix, an in vitro diagnostic test for prostate cancer, approved for sale in the European Union. Additionally, it is focused on marketing Proclarix in the U.S. as a lab-developed product. Onconetix operates in one segment: commercial. Geographically, the company generates maximum revenue from Switzerland and the rest from the United Kingdom.